NEW YORK, March 19, 2018 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, is pleased to announce the launch of the INR Wellness immune support product line.
INR Wellness is a once-daily nutritional supplement that contains yeast, oat, and mushroom beta-glucans. These three naturally occurring beta-glucans have been shown across hundreds of clinical studies to support the human immune system and are commonly used as an OTC supplement to reduce cholesterol levels, manage blood glucose levels, and to support the immune system in people whose body defenses have been weakened by conditions such as chronic fatigue, or physical and emotional stress; or by treatments such as radiation or chemotherapy.
Immudyne’s INR Wellness product is the first in the world with a proprietary triple-action formulation that contains what we believe to be the most important beta glucans for overall immune support.
“We’re excited to add another revenue stream to Immudyne’s portfolio,” stated Justin Schreiber, President & CEO of Immudyne. “We believe INR Wellness is the highest quality immune support product on the market and presents a significant growth opportunity for the Company.”
Immudyne will begin sales of INR Wellness on Monday, March 19th, 2018 through the Company’s website. A national Facebook, Google and Amazon campaign will commence shortly thereafter.
“In 2017, the U.S. nutritional supplement and vitamin market was approximately $36.1 billion,” stated Stefan Galluppi, Chief Technology and Operating Officer of Immudyne. “The immune support vertical is an attractive segment of the supplement market that has seen little innovation in recent years. Given the extensive clinical data and proprietary formulation of INR Wellness, we believe we're well positioned for a successful product launch.”
For more information on INR Wellness or to purchase the product, please visit https://www.inrwellness.com/.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is an online direct response marketing company that builds innovative and proprietary health and wellness brands that transform and enrich the lives of consumers around the world. Immudyne’s scalable and global advertising technology infrastructure leverages the world’s largest social media and online sales platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.immudyne.com or email us at [email protected].


Shein Shares Drop 5% After Weak Hong Kong IPO Debut
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Star Entertainment Shares Fall After A$307 Million FY2026 Loss
OpenAI Nears Astra AI Model Launch With Safety Focus
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question
France Targets Shein, Temu With Fast-Fashion Fees
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return
Faraday Future Delivers First Robots in Middle East, Plans September Launches
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses
CATL Shares Fall as Hungary Plant Faces Safety Halt
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 



